Skip to main content

Table 1 Ex vivo susceptibility to standard anti-malarial drugs of 32 Plasmodium falciparum isolates from Dakar collected from September 2014 to November 2015. The results were compared to the P. falciparum W2 clone tested under the same conditions

From: Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015

Drugs Isolate IC50 mean
[CI 95%]
W2 IC50 mean
[CI 95%]
Resistance cut-off % (no) of reduced susceptibility
Monodesethylamodiaquine 28.9 nM
[21.3–39.0]
75 nM
[70–80]
61 nM 28.1 (9/32)
Chloroquine 62.2 nM
[35.0–110.6]
324 nM
[199–351]
77 nM 46.9 (15/32)
Lumefantrine 3.5 nM
[2.3–5.2]
12.4 nM
[9.7–18.3]
115 nM 0 (0/32)
Mefloquine 26.0 nM
[18.4–36.7]
18.3 nM
[16.8–19.0]
30 nM 45.2 (14/31)
Quinine 220.6 nM
[157.6–308.7]
294 nM
[277–314]
611 nM 9.7 (3/31)
Piperaquine 36.5 nM
[26.5–50.4]
31.5 nM
[28.8–34.4]
135 nM 0 (0/30)
Pyronaridine 8.7 nM
[5.8–13.2]
26.0 nM
[21.5–25.7]
60 nM 0 (0/30)
Dihydroartemisinin 1.54 nM
[0.99–2.39]
1.35 nM
[1.14–1.60]
12 nM 0 (0/28)
Artesunate 2.13 nM
[1.27–3.59]
1.63 nM
[1.41–1.92]
12 nM 0 (0/28)
Doxycycline 25.7 µM
[19.5–33.9]
11.3 µM
[10.0–12.7]
37 µM 31.2 (10/32)
  1. CI 95% confident interval 95%
  2. The W2 clone IC50 means are the results of four independent experiments